Equity Performance & Market Positioning
AMGN — Performance
| Period | Return | vs S&P 500 |
|---|---|---|
| 1 Month | -8.1% | -0.2% |
| 3 Month | 4.4% | 12.6% |
| 6 Month | 28.6% | 32.2% |
| YTD | 6.6% | 13.5% |
| 1 Year | 16.0% | 4.5% |
| 2 Year (Ann.) | 14.1% | 3.6% |
| 3 Year (Ann.) | 17.5% | 0.2% |
| 5 Year (Ann.) | 10.4% | 0.2% |
| 10 Year (Ann.) | 12.2% | 0.2% |
| Full History (Ann.) | 18.6% | 10.6% |
| Risk Metric | Value |
|---|---|
| Volatility (20D Ann.) | 21.4% |
| Beta | 0.42 |
| Sharpe Ratio | 0.54 |
| Max Drawdown (1Y) | -15.8% |
| RSI (14) | 20 |
| 52W Range Position | 68% |
| Ownership | Value |
|---|---|
| Institutional Ownership | 81.0% |
| Ownership Change (QoQ) | +2.6% |
| Insider Buy/Sell Ratio | 6.19 |
| Insider Sentiment | Bullish |
Revenue, Earnings & Margin History
Amgen’s revenue trajectory reflects a deliberate pivot toward volume-driven growth, achieving a $36.8 billion top line supported by a three-year CAGR of 11.8%. This expansion is increasingly underpinned by the successful integration of high-value acquisitions and the scaling of the rare disease and inflammation franchises, which have effectively mitigated pricing headwinds in the legacy biologic portfolio. The 9.95% year-over-year revenue increase demonstrates robust commercial execution, particularly as the company transitions its product mix toward newer clinical assets with longer patent runways. Over the next 6-18 months, the sustainability of this growth will depend on the continued market penetration of the general medicine and oncology segments, alongside the stabilization of the biosimilars business.
AMGN — 11 Years of Data
Revenue 3Y CAGR: 11.8% | 5Y CAGR: 7.6% | EPS 3Y CAGR: 5.5%
| Year | Revenue | YoY% | Gross% | Op% | Net% | EBITDA% | EPS | R&D/Rev | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $36.8B | 10.0% | 82.5% | 40.5% | 21.0% | 46.6% | $14.23 | 19.8% | 0.0% |
| 2024 | $33.4B | 18.6% | 61.5% | 21.7% | 12.2% | 40.0% | $7.56 | 17.8% | 1.6% |
| 2023 | $28.2B | 7.1% | 70.1% | 28.0% | 23.8% | 52.5% | $12.49 | 17.0% | 1.5% |
| 2022 | $26.3B | 1.3% | 75.7% | 36.3% | 24.9% | 46.2% | $12.11 | 16.8% | 1.5% |
| 2021 | $26.0B | 2.2% | 75.2% | 29.4% | 22.7% | 43.5% | $10.28 | 24.3% | 1.3% |
| 2020 | $25.4B | 8.8% | 75.8% | 35.9% | 28.6% | 51.1% | $12.31 | 16.5% | 1.3% |
| 2019 | $23.4B | -1.6% | 81.4% | 41.4% | 33.6% | 54.1% | $12.88 | 17.6% | 1.3% |
| 2018 | $23.7B | 3.9% | 82.7% | 43.2% | 35.3% | 54.3% | $12.62 | 15.7% | 1.3% |
| 2017 | $22.8B | -0.6% | 82.2% | 43.6% | 8.7% | 56.3% | $2.69 | 15.6% | 1.4% |
| 2016 | $23.0B | 6.1% | 81.9% | 42.6% | 33.6% | 54.5% | $10.24 | 16.7% | 1.4% |
| 2015 | $21.7B | 80.5% | 39.1% | 32.0% | 51.6% | $9.06 | 18.8% | 1.5% |
Key Findings
- Operating efficiency remains high with gross margins expanding to 82.5% and operating margins reaching 40.5%, though net margins contracted to 21.0% due to non-operating expenses and acquisition-related financing costs.
- The company maintains a high-intensity innovation model, allocating 19.8% of total revenue to R&D, which is essential for pipeline replenishment as legacy assets face biosimilar competition.
- A significant divergence between operating performance and net profitability exists, with an EPS of $14.23 being pressured by the capital structure adjustments required to fund inorganic growth initiatives.
Profitability & Return on Capital
Amgen’s return on equity (ROE) profile has undergone a structural transformation, escalating from 24.7% to 89.1%. This expansion is not a function of margin expansion—which contracted from 32.0% to 21.0% due to integration costs and shifting product mix—but rather a significant recalibration of capital structure and asset utilization. The Equity Multiplier surged from 2.55 to 10.46, reflecting the substantial debt load incurred to fund strategic acquisitions, most notably the Horizon Therapeutics transaction. Simultaneously, Asset Turnover improved from 0.30 to 0.41, signaling enhanced efficiency in generating revenue from a larger, diversified asset base. This transition indicates a shift toward a more aggressive, levered capital model designed to maximize shareholder returns during a period of portfolio transition. Despite the margin compression, the company maintains a formidable Return on Invested Capital (ROIC) of 28.4%, significantly exceeding its weighted average cost of capital and affirming its status as a premier value creator in the biotechnology space. A critical component of this efficiency is its negative Cash Conversion Cycle (CCC) of -738 days. This atypical working capital structure, driven by high levels of deferred revenue and strategic payables management, allows the business to operate as a net provider of liquidity. This liquidity profile, combined with robust free cash flow generation, provides the necessary buffer to service its elevated debt obligations while continuing to invest in its high-conviction pipeline, particularly in oncology and immunology.
AMGN — DuPont Decomposition
| Component | First (2015) | Latest (2025) | Trend |
|---|---|---|---|
| ROE | 24.7% | 89.1% | 64.4pp |
| = Net Margin | 32.0% | 21.0% | |
| × Asset Turnover | 0.30x | 0.41x | |
| × Equity Multiplier | 2.55x | 10.46x |
| Return Metric | Value |
|---|---|
| ROIC | 28.4% |
| ROA | 8.5% |
| ROCE | 22.9% |
| Efficiency | Value |
|---|---|
| Asset Turnover | 0.41x |
| Fixed Asset Turnover | 4.64x |
| Inventory Turnover | 1.0x |
| Receivables Turnover | 3.8x |
| Payables Turnover | 0.3x |
| Cash Conversion Cycle | -738 days |
Key Findings
- ROE expansion to 89.1% is predominantly leverage-driven (EM 10.46), reflecting a strategic shift toward an inorganic growth model financed by debt, which offsets the 1,100 bps compression in net margins.
- A negative CCC of -738 days represents a significant competitive advantage in liquidity management, allowing the company to effectively fund operations through its working capital cycle.
- Sustained ROIC of 28.4% demonstrates that despite margin dilution to 21.0%, the underlying business model remains highly accretive, generating substantial economic profit over its cost of capital.
Balance Sheet & Cash Flow Health
Amgen’s capital structure currently reflects a significant expansion of leverage following the $27.8 billion acquisition of Horizon Therapeutics, resulting in a Debt-to-Equity ratio of 6.31. While this figure indicates a highly geared balance sheet, solvency concerns are mitigated by a robust Interest Coverage ratio of 5.41x, which confirms that operating earnings remain more than sufficient to service heightened interest obligations. The liquidity profile, defined by a Current Ratio of 1.14, suggests a disciplined approach to working capital management, providing just enough coverage for short-term liabilities while prioritizing the deployment of excess cash toward debt reduction and R&D investment. Over the next 6-18 months, the company's financial health will be contingent on its ability to execute a rapid deleveraging cycle, supported by its established portfolio of biologic therapies. Cash flow quality remains a primary pillar of the long-term investment case, characterized by a Free Cash Flow (FCF) margin of 22.0% and an OCF/NI ratio of 1.29x. This strong cash-to-earnings conversion ratio highlights the high quality of reported net income, as operational cash flows significantly exceed accounting profits due to substantial non-cash amortization charges related to acquired intellectual property. This cash flow generation provides the enterprise with the flexibility to maintain its dividend policy and fund its late-stage clinical pipeline without requiring external financing. The sustainability of these margins, even amidst inflationary pressures and pricing regulations, underscores the competitive advantage inherent in Amgen's manufacturing scale and specialized biologics portfolio.
AMGN — Balance Sheet Health
| Metric | Value | Threshold |
|---|---|---|
| Current Ratio | 1.14x | > 1.5x Strong |
| Quick Ratio | 1.14x | > 1.0x Strong |
| Debt/Equity | 6.31x | < 1.0 Conservative |
| Interest Coverage | 5.4x | > 5x Strong |
| Net Debt/EBITDA | 2.7x | < 2x Low |
AMGN — Cash Flow History
| Year | Operating CF | CapEx | FCF | FCF Margin | OCF/NI | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| 2025 | $9958M | $-1858M | $8100M | 22.0% | 1.29x | ||
| 2024 | $11490M | $-1096M | $10394M | 31.1% | 2.81x | $-200M | $-4832M |
| 2023 | $8471M | $-1112M | $7359M | 26.1% | 1.26x | $-4556M | |
| 2022 | $9721M | $-936M | $8785M | 33.4% | 1.48x | $-6360M | $-4196M |
| 2021 | $9261M | $-880M | $8381M | 32.3% | 1.57x | $-4975M | $-4013M |
| 2020 | $10497M | $-608M | $9889M | 38.9% | 1.45x | $-3486M | $-3755M |
| 2019 | $9150M | $-618M | $8532M | 36.5% | 1.17x | $-7702M | $-3509M |
| 2018 | $11296M | $-738M | $10558M | 44.5% | 1.35x | $-17794M | $-3507M |
| 2017 | $11177M | $-664M | $10513M | 46.0% | 5.65x | $-3160M | $-3365M |
| 2016 | $10354M | $-837M | $9517M | 41.4% | 1.34x | $-2965M | $-2998M |
| 2015 | $9077M | $-649M | $8428M | 38.9% | 1.31x | $-1867M | $-2396M |
Key Findings
- Elevated solvency risk from a 6.31 Debt-to-Equity ratio is effectively countered by a 5.41x Interest Coverage ratio, ensuring stable debt service capacity post-acquisition.
- Superior earnings quality is evidenced by an OCF/NI ratio of 1.29x and a 22.0% FCF margin, providing the necessary liquidity to fund both deleveraging and internal growth initiatives.
- A lean liquidity position (1.14 Current Ratio) necessitates disciplined capital allocation and operational efficiency over the 18-month outlook to manage maturing debt obligations.
Executive Insights & Key Takeaways
Amgen Inc. demonstrates a robust financial profile characterized by a $36.8 billion revenue base and a significant 11.77% CAGR, reflecting successful commercial execution and the integration of strategic acquisitions. The company’s operating efficiency is evidenced by a 20.98% net margin and a superior 28.40% return on invested capital (ROIC), indicating that capital deployed into its clinical pipeline and market expansion is generating returns well above its weighted average cost of capital. Furthermore, a free cash flow (FCF) margin of 22.04% provides the necessary liquidity to service obligations while continuing to fund high-value R&D initiatives and shareholder distributions. Despite these operational strengths, the capital structure reveals elevated leverage with a debt-to-equity ratio of 6.31, primarily a byproduct of aggressive inorganic growth strategies aimed at diversifying the therapeutic portfolio. While the current ratio of 1.14 suggests adequate short-term liquidity, the strategic focus over the next 6-18 months will likely center on the deleveraging of the balance sheet and the realization of operational synergies from recent large-scale acquisitions. The company’s low beta of 0.425 underscores its defensive positioning, offering a lower correlation to broader market volatility, which is particularly advantageous for risk-adjusted portfolio construction in the current macroeconomic environment.
Key Takeaways
- Exceptional capital productivity is highlighted by an 89.06% ROE and 28.40% ROIC, signaling high management efficacy in resource allocation and pipeline development.
- Strong cash flow generation, evidenced by a 22.04% FCF margin, provides a critical buffer for servicing the company's substantial debt load and funding late-stage clinical trials.
- The elevated debt-to-equity ratio of 6.31 necessitates disciplined capital management and successful integration of acquired assets to maintain credit stability and support future expansion.
- A low beta of 0.425 and 21.40% volatility profile position the business as a defensive core holding capable of providing stability during periods of market turbulence.
- Consistent top-line expansion with an 11.77% CAGR confirms the company's ability to offset legacy product erosion through new product launches and market share gains.